EC: 1.4.3.4
monoamine oxidase (amine:oxygen oxidoreductase (deaminating))
Pathways
| pathway id | name |
|---|---|
| BioCyc:HUMAN_PWY-6307 | tryptophan degradation via tryptamine |
| BioCyc:HUMAN_PWY66-401 | superpathway of tryptophan utilization |
| BioCyc:HUMAN_PWY-6402 | superpathway of melatonin degradation |
| BioCyc:META_PWY-6307 | L-tryptophan degradation X (mammalian, via tryptamine) |
| BioCyc:META_PWY6666-2 | dopamine degradation |
| BioCyc:META_PWY-6313 | serotonin degradation |
| BioCyc:META_PWY-6342 | noradrenaline and adrenaline degradation |
| BioCyc:MOUSE_THRDLCTCAT-PWY | threonine degradation III (to methylglyoxal) |
| BioCyc:HUMAN_PWY-6313 | serotonin degradation |
| BioCyc:META_PWY-0 | putrescine degradation III |
| BioCyc:MOUSE_PWY6666-2 | dopamine degradation |
| BioCyc:HUMAN_PWY6666-2 | dopamine degradation |
| BioCyc:HUMAN_PWY-0 | putrescine degradation III |
| BioCyc:HUMAN_PWY-6342 | noradrenaline and adrenaline degradation |
| BioCyc:HUMAN_PWY-6399 | melatonin degradation II |
| BioCyc:META_PWY-6318 | L-phenylalanine degradation IV (mammalian, via side chain) |
| BioCyc:MOUSE_PWY-0 | putrescine degradation III |
| Reactome:R-BTA-1430728 | Metabolism |
| Reactome:R-BTA-211945 | Phase I - Functionalization of compounds |
| Reactome:R-BTA-112310 | Neurotransmitter release cycle |
| Reactome:R-BTA-379397 | Enzymatic degradation of dopamine by COMT |
| Reactome:R-DRE-112315 | Transmission across Chemical Synapses |
| Reactome:R-DRE-112311 | Neurotransmitter clearance |
| Reactome:R-DRE-380615 | Clearance of seratonin |
| Reactome:R-DRE-140179 | Amine Oxidase reactions |
| Reactome:R-HSA-211859 | Biological oxidations |
| Reactome:R-HSA-112315 | Transmission across Chemical Synapses |
| Reactome:R-HSA-112311 | Neurotransmitter clearance |
| Reactome:R-HSA-380615 | Clearance of seratonin |
| Reactome:R-HSA-1643685 | Disease |
| Reactome:R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling |
| Reactome:R-MMU-1430728 | Metabolism |
| Reactome:R-MMU-211859 | Biological oxidations |
| Reactome:R-MMU-181430 | Norepinephrine Neurotransmitter Release Cycle |
| Reactome:R-MMU-379398 | Enzymatic degradation of Dopamine by monoamine oxidase |
| Reactome:R-RNO-211945 | Phase I - Functionalization of compounds |
| Reactome:R-RNO-112316 | Neuronal System |
| Reactome:R-RNO-379401 | Clearance of dopamine |
| Reactome:R-RNO-380612 | Metabolism of serotonin |
| Reactome:R-BTA-211859 | Biological oxidations |
| Reactome:R-BTA-112316 | Neuronal System |
| Reactome:R-BTA-379401 | Clearance of dopamine |
| Reactome:R-BTA-380612 | Metabolism of serotonin |
| Reactome:R-DRE-181430 | Norepinephrine Neurotransmitter Release Cycle |
| Reactome:R-DRE-379398 | Enzymatic degradation of Dopamine by monoamine oxidase |
| Reactome:R-DRE-211945 | Phase I - Functionalization of compounds |
| Reactome:R-HSA-141333 | Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB |
| Reactome:R-HSA-181430 | Norepinephrine Neurotransmitter Release Cycle |
| Reactome:R-HSA-379398 | Enzymatic degradation of Dopamine by monoamine oxidase |
| Reactome:R-HSA-5579012 | Defective MAOA causes BRUNS |
| Reactome:R-HSA-449147 | Signaling by Interleukins |
| Reactome:R-MMU-141333 | Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB |
| Reactome:R-MMU-112310 | Neurotransmitter release cycle |
| Reactome:R-MMU-379397 | Enzymatic degradation of dopamine by COMT |
| Reactome:R-RNO-211859 | Biological oxidations |
| Reactome:R-RNO-112315 | Transmission across Chemical Synapses |
| Reactome:R-RNO-112311 | Neurotransmitter clearance |
| Reactome:R-RNO-380615 | Clearance of seratonin |
| Reactome:R-BTA-140179 | Amine Oxidase reactions |
| Reactome:R-BTA-181430 | Norepinephrine Neurotransmitter Release Cycle |
| Reactome:R-BTA-379398 | Enzymatic degradation of Dopamine by monoamine oxidase |
| Reactome:R-DRE-112316 | Neuronal System |
| Reactome:R-DRE-379401 | Clearance of dopamine |
| Reactome:R-DRE-380612 | Metabolism of serotonin |
| Reactome:R-DRE-1430728 | Metabolism |
| Reactome:R-DRE-141333 | Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB |
| Reactome:R-HSA-211945 | Phase I - Functionalization of compounds |
| Reactome:R-HSA-112316 | Neuronal System |
| Reactome:R-HSA-379401 | Clearance of dopamine |
| Reactome:R-HSA-380612 | Metabolism of serotonin |
| Reactome:R-HSA-5668914 | Diseases of metabolism |
| Reactome:R-HSA-5579029 | Metabolic disorders of biological oxidation enzymes |
| Reactome:R-HSA-168256 | Immune System |
| Reactome:R-MMU-211945 | Phase I - Functionalization of compounds |
| Reactome:R-MMU-112315 | Transmission across Chemical Synapses |
| Reactome:R-MMU-112311 | Neurotransmitter clearance |
| Reactome:R-MMU-380615 | Clearance of seratonin |
| Reactome:R-RNO-1430728 | Metabolism |
| Reactome:R-RNO-140179 | Amine Oxidase reactions |
| Reactome:R-RNO-112310 | Neurotransmitter release cycle |
| Reactome:R-RNO-379397 | Enzymatic degradation of dopamine by COMT |
| Reactome:R-BTA-141333 | Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB |
| Reactome:R-BTA-112315 | Transmission across Chemical Synapses |
| Reactome:R-BTA-112311 | Neurotransmitter clearance |
| Reactome:R-BTA-380615 | Clearance of seratonin |
| Reactome:R-DRE-112310 | Neurotransmitter release cycle |
| Reactome:R-DRE-379397 | Enzymatic degradation of dopamine by COMT |
| Reactome:R-DRE-211859 | Biological oxidations |
| Reactome:R-HSA-1430728 | Metabolism |
| Reactome:R-HSA-140179 | Amine Oxidase reactions |
| Reactome:R-HSA-112310 | Neurotransmitter release cycle |
| Reactome:R-HSA-379397 | Enzymatic degradation of dopamine by COMT |
| Reactome:R-HSA-1280215 | Cytokine Signaling in Immune system |
| Reactome:R-MMU-140179 | Amine Oxidase reactions |
| Reactome:R-MMU-112316 | Neuronal System |
| Reactome:R-MMU-379401 | Clearance of dopamine |
| Reactome:R-MMU-380612 | Metabolism of serotonin |
| Reactome:R-RNO-141333 | Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB |
| Reactome:R-RNO-181430 | Norepinephrine Neurotransmitter Release Cycle |
| Reactome:R-RNO-379398 | Enzymatic degradation of Dopamine by monoamine oxidase |
| WikiPathways:WP5298 | Dravet syndrome: Scn1a-A1783V point mutation model |
| WikiPathways:WP4157 | GABA metabolism (aka GHB) |
| WikiPathways:WP5372 | Involvement of -secretase in neurodegenerative diseases |
| WikiPathways:WP4156 | Biosynthesis and regeneration of tetrahydrobiopterin and catabolism of phenylalanine |
| PathBank:SMP0120540 | Phenylketonuria |
| PathBank:SMP0000190 | Hawkinsinuria |
| PathBank:SMP0000242 | Dimethylglycine Dehydrogenase Deficiency |
| PathBank:SMP0000223 | Non-Ketotic Hyperglycinemia |
| PathBank:SMP0000484 | Dimethylglycine Dehydrogenase Deficiency |
| PathBank:SMP0120471 | Cystathionine beta-Synthase Deficiency |
| PathBank:SMP0120487 | Glycine N-Methyltransferase Deficiency |
| PathBank:SMP0120511 | Tyrosinemia Type 3 (TYRO3) |
| PathBank:SMP0120519 | Methionine Adenosyltransferase Deficiency |
| PathBank:SMP0120527 | S-Adenosylhomocysteine (SAH) Hydrolase Deficiency |
| PathBank:SMP0000004 | Glycine and Serine Metabolism |
| PathBank:SMP0000169 | Alkaptonuria |
| PathBank:SMP0000429 | Disulfiram Action Pathway |
| PathBank:SMP0000721 | 3-Phosphoglycerate Dehydrogenase Deficiency |
| PathBank:SMP0063637 | Methionine Metabolism |
| PathBank:SMP0120461 | Canavan Disease |
| PathBank:SMP0120513 | Tyrosinemia Type 2 (or Richner-Hanhart Syndrome) |
| PathBank:SMP0120634 | Homocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type |
| PathBank:SMP0000044 | Histidine Metabolism |
| PathBank:SMP0000191 | Histidinemia |
| PathBank:SMP0000218 | Tyrosinemia Type I |
| PathBank:SMP0000179 | Dihydropyrimidine Dehydrogenase Deficiency (DHPD) |
| PathBank:SMP0000485 | Hyperglycinemia, Non-Ketotic |
| PathBank:SMP0000533 | Monoamine Oxidase-A Deficiency (MAO-A) |
| PathBank:SMP0120498 | Hypermethioninemia |
| PathBank:SMP0120502 | Hypoacetylaspartia |
| PathBank:SMP0000006 | Tyrosine Metabolism |
| PathBank:SMP0000244 | Sarcosinemia |
| PathBank:SMP0000424 | Citalopram Action Pathway |
| PathBank:SMP0000494 | Tyrosinemia, Transient, of the Newborn |
| PathBank:SMP0000498 | Dopamine beta-Hydroxylase Deficiency |
| PathBank:SMP0000627 | Citalopram Metabolism Pathway |
| PathBank:SMP0063597 | Aspartate Metabolism |
| PathBank:SMP0063649 | Phenylalanine and Tyrosine Metabolism |